Therapeutic targeting of the p53 tumor suppressor gene

Current Opinion in Biotechnology

Volumn 7, Issue 6, 1996, Pages 592-600

  Beaudry, Gary A ^a   Bertelsen, Arthur H ^a   Sherman, Michael I ^a  

^a PharmaGenics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; PROTEIN P53; VIRUS PROTEIN;

APOPTOSIS; CANCER; CELL DIVISION; GENE THERAPY; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0030560838     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(96)80069-3     Document Type: Article

References (90)

1. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 253:1991;49-53.
2. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet. 1:1992;45-49.
3. Funk WD, Pak DT, Karas RH, Wright WE, Shay JW. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol. 12:1992;2866-2871.
4. Pietenpol JA, Tokino T, Thiagalingam S, El-Deiry WS, Kinzler KW, Vogelstein B. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci USA. 91:1994;1998-2002.
5. Caelles C, Helmberg A, Karin M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature. 370:1994;220-223.
6. Lane DP. p53, guardian of the genome. Nature. 358:1992;15-16.
7. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science. 256:1992;827-830.
8. Milner J, Medcalf EA. Contranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell. 65:1991;765-774.
9. Friedman PN, Chen X, Bargonetti J, Prives C. The p53 protein in an unusually shaped tetramer that binds directly to DNA. Proc Natl Acad Sci USA. 90:1993;3319-3323.
10. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:1991;6304-6311.
11. Zhan Q, Carrier F, Fornace AJ. Induction of cellular p53 activity by DNA-damaging agents and growth arrest. Mol Cell Biol. 13:1993;4242-4250.
12. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:1993;957-967.
13. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. of outstanding interest Nature. 379:1996;88-91 Hypoxia, which is found in poorly vascularized parts of tumors, is demonstrated to induce p53-dependent apoptosis. Highly apoptotic regions in tumors were found to correlate with both hypoxia and wild-type p53. The authors propose that hypoxia provides a physiological selective pressure in tumors such that cells containing mutant p53 escape apoptosis and have a proliferative advantage that contributes to tumor expansion.
14. Anthoney DA, McIlwrath AJ, Gallagher WM, Edlin ARM, Brown R. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Res. 56:1996;1374-1381.
15. Moll UM, Ostermeyer AG, Ahomadegbe JC, Matheu MC, Riou G. p53 mediated tumor cell response to chemotherapeutic DNA damage: a preliminary study in matched pairs of breast cancer biopsies. Hum Pathol. 26:1995;1293-1301.
16. Heimdal K, Lothe RA, Lystad S, Holm R, Fossa SD, Borresen AL. No germline TP53 mutations detected in familial and bilateral testicular cancer. Genes Chromosom Cancer. 6:1993;92-97.
17. Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT, Knowles DM, Dalla-Favera R. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 88:1991;5413-5417.
18. Wu GS, El-Deiry WS. Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 of Bcl-2. of special interest Clin Cancer Res. 2:1996;623-633 A study demonstrating that cells responding well to lethal doses of chemotherapeutic drugs do so independently of a p53-mediated response or the Bcl-2 : Bax ratios present in the cell. The authors suggest that although p53 status may be a determining factor in some cell types, a more consistent predictor of chemosensitivity is the in vitro measurement of induction of apoptosis.
19. Al-Azraqi A, Chapman C, Challen C, Sigalas J, Aswaad S, Sinha D, Calvert AH, Lunec J. p53 alterations in ovarian cancer as a determinant of response to carboplatin. Br J Cancer. 69:1994;7-15.
20. Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, Galloway DA. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med. 2:1996;72-79.
21. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. of outstanding interest Cancer Res. 55:1995;5187-5190 See annotation [23].
22. waf1/cip1 -/- human cancer cells. of outstanding interest Cancer Res. 56:1996;2250-2255 See annotation [23].
23. waf1,cip1 is involved in the normal coupling of S and M phases of the cell cycle.
24. cip1/waf1 undergo normal development but are defective in, G1 checkpoint control. Cell. 82:1995;675-684.
25. Chen IT, Akamatsu M, Smith ML, Lung F-DT, Duba D, Roller PP, Fornace AJ, O'Conner PM. Characterization of p21cip1/waf1 peptide domains required for cyclin E/Cdk2 and PCNA interaction. of special interest Oncogene. 12:1996;595-607 See annotation [27].
26. Fotedar R, Fitzgerald P, Rousselle T, Cannella D, Doree M, Messier H, Fotedar A. p21 contains independent binding sites for cyclin and cdk2: both sites are required to inhibit cdk2 kinase activity. of special interest Oncogene. 12:1996;2155-2164 See annotation [27].
27. waf1,cip1 are required to bind in inhibit cyclin-dependent kinase: the first domain (amino acids 15-40) binds cyclin E-CDK2 and inhibits kinase, whereas the second domain (amino acids 58-77) binds cyclin E-CDK2 but does not inhibit kinase. A third domain, approximately amino acids 139-164, binds PCNA.
28. Bravo R, Frank R, Blundell PA, Macdonald-Bravo H. Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta. Nature. 326:1987;515-517.
29. Prelich G, Tan CK, Kostura M, Mathews MB, So AG, Downey KM, Stillman B. Functional identity of proliferating cell nuclear antigen and a DNA polymerase-delta auxiliary protein. Nature. 326:1987;517-520.
30. Li R, Waga S, Hannon GJ, Beach D, Stillman B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature. 371:1994;534-537.
31. Fukasawa K, Choi T, Kuriyama R, Rulong S, Vande Woude GF. Abnormal centrosome amplification in the absence of p53. of outstanding interest Science. 271:1996;1744-1747 Mouse embryo fibroblasts lacking p53 are shown to contain multiple copies of functionally competent centrosomes. Although there was no apparent increase in centrosome number in early versus late passage p53-/- cells, (possibly due to selection gainst cells with more than three centrosomes), serum stimulation of cells previously growth-arrested showed a 40% decline in the number of cells containing a single centrosome (with a corresponding increase in cells containing two or more centrosomes), compared to p53+/+ cells which showed only a 10% decrease in cells containing a single centrosome. Thus, it is proposed that p53 maintains genomic stability through regulation of centrosome duplication.
32. White E. Life, death, and the pursuit of apoptosis. Genes Dev. 10:1996;1-15.
33. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 9:1996;1799-1805.
34. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 80:1995;293-299.
35. Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang WW, Kruzel E. Wildtype human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol. 15:1995;3032-3040.
36. Boddy MN, Freemont PS, Borden KLB. The p53-associated protein MDM2 contains a newly characterized zinc-binding domain called the RING finger. Trends Biochem Sci. 19:1994;10-11.
37. Oliner JD, Kinzler KW, Melzers PS, George D, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 358:1992;80-83.
38. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 362:1993;857-860.
39. Reifenberger G, Liu L, Ichimur K, Schmidt EE, Collins VP. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutation. Cancer Res. 53:1993;2736-2739.
40. Haupt Y, Barak Y, Oren M. Cell type-specific inhibition of p53-mediated apoptosis by MDM2. of outstanding interest EMBO J. 15:1996;1596-1606 See annotation [43].
41. Chen J, Wu X, Lin J, Levine AJ. Mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. of outstanding interest Mol Cell Biol. 16:1996;2445-2452 See annotation [43].
42. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. of outstanding interest Nature. 378:1995;206-208 See annotation [43].
43. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. of outstanding interest Nature. 378:1995;203-206 This paper, together with [40-42], directly confirms one function of MDM2; to block wild-type p53 induction of G1 arrest and apoptosis. It was known prior to these reports that MDM2 could bind p53 and prevent p53-dependent transcriptional activation of target genes, that tumor cells that had elevated MDM2 also contained wild-type p53 and that tumor cells with elevated MDM2 were defective in G1 checkpoint controls. References [42] and [43] directly address the role of MDM2 in early embryonic development and show that wild-type p53 activity is lethal to embryos at day 5 unless MDM2 is present to suppress this activity. References [40] and [41] demonstrate that MDM2 inhibits wild-type p53-mediated G1 arrest and apoptosis. Together these reports establish a role of MDM2 in tumorigenesis and validate MDM2 as an important therapeutic target for drug discovery efforts.
44. Xiao ZX, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR, Livingston DM. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature. 375:1995;694-698.
45. Martin K, Trouche D, Hagemeier C, Sorensen TS, La Thangue NB, Kouzarides T. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature. 375:1995;691-694.
46. Picksley SM, Vojtesek B, Sparks A, Lane DP. Immunochemical analysis of the interaction of p53 with MDM2; -fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene. 9:1994;2523-2529.
47. Wu X, Levine AJ. p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci USA. 91:1994;3602-3606.
48. Yamasaki L, Jacks T, Bronson R, Goillot E, Harlow E, Dyson NJ. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell. 85:1996;537-548.
49. Field SJ, Tsai F-Y, Kuo F, Zubiaga AM, Kaelin WG, Livingston DM, Orkin SH, Greenberg ME. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell. 85:1996;549-561.
50. Huibregtse JM, Scheffner M, Howley PM. E6-AP directs the HPV E6-dependent inactivation of p53 and is representative of a family of structurally and functionally related proteins. Cold Spring Harb Symp Quant Biol. 59:1994;237-245.
51. Klingeshutz AJ, Foster SA, McDougall JK. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature. 380:1996;79-82.
52. Blasco MA, Rizen M, Greider CW, Hanahan D. Differential regulation of telomerase activity and telomerase RNA during multi-stage tumorigenesis. Nat Genet. 12:1996;200-204.
53. Harris CC. The 1995 Walter Hubert Lecture - molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumour-suppressor gene. Br J Cancer. 73:1996;261-269.
54. Benn J, Schneider RJ. Hepatitis B virus HBx protein deregulates cell cycle checkpoint controls. Proc Natl Acad Sci USA. 92:1995;11215-11219.
55. Takada S, Tsuchida N, Kobayashi M, Koike K. Disruption of the function of tumor-suppressor gene p53 by the hepatitis B virus X protein and hepatocarcinogenesis. J Cancer Res Clin Oncol. 121:1995;593-601.
56. Wang XW, Vermeulen W, Coursen JD, Gibson M, Lupold SE, Forrester K, Xu G, Elmore L, Yeh H, Hoeijmakers JHJ, Harris CC. The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev. 10:1996;1219-1232.
57. Wang XW, Gibson MK, Vermeulen W, Yeh H, Forrester K, Sturzbecher HW, Hoeijmakers JH, Harris CC. Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Res. 55:1995;6012-6016.
58. Speir E, Modali R, Huang ES, Leon MB, Shawl F, Finkel T, Epstein SE. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science. 265:1994;391-394.
59. Moll UM, LaQuaglia M, Benard J, Riou G. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in different tumors. Proc Natl Acad Sci USA. 92:1995;4407-4411.
60. Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA. 89:1992;7262-7266.
61. Moll UM, Ostermeyer AG, Haladay R, Winkfield B, Frazier M, Zambetti G. Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. of special interest Mol Cell Biol. 16:1996;1126-1137 Despite early reports (see reference [60]) demonstrating cytoplasmic retention of wild-type p53, little information was available relating cytoplasmic sequestration to functional inactivation. The authors in this report demonstrate that the cytoplasmic retention of wild-type p53 seen in neuroblastoma cells is sufficient to impair p53-mediated G1 arrest in response to DNA damage. Interestingly, the authors also show that cytoplasmic retention of p53 is saturable, because nuclear accumulation of p53 occurs at high doses of DNA-damaging agent. These data suggest that the molecule(s) responsible for cytoplasmic retention of p53 might be an appropriate target for drug discovery.
62. Swift M, Reitnauer PJ, Morrell D, Chase CL. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med. 316:1987;1289-1294.
63. Hecht F, Hecht BK. Cancer in ataxia-telangiectasia patients. Cancer Genet Cytogenet. 46:1990;9-19.
64. Scott D, Spreadborough AR, Roberts SA. Radiation-induced G2 delay and spontaneous chromosome aberrations in ataxia-telangiectasia homozygotes and heteroxygotes. Int J Radiat Biol. 66:1994;S157-S163.
65. Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 71:1992;587-597.
66. Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, Tagle DA, Smith S, Uziel T, Sfez S. A single ataxia telangiectasia gene with a product similar to Pl-3 kinase. Science. 268:1995;1749-1753.
67. Savitsky K, Sfez S, Tagle DA, Ziv Y, Sartiel A, Collins FSSY, Rotman G. The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Hum Mol Genet. 4:1995;2025-2032.
68. Price BD, Youmell MB. The phosphatidylinosital 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage. Cancer Res. 56:1996;246-250.
69. Shiohara M, El-Deiry WS, Wada M, Nakamaki T, Takeuchi S, Yang R, Chen DL, Vogelstein B, Koeffler HP. Absence of WAF1 mutations in a variety of human malignancies. Blood. 84:1994;3781-3784.
70. Fujiwara T, Grimm EA, Roth JA. Gene therapeutics and gene therapy for cancer. Curr Opin Oncol. 6:1994;96-105.
71. Cai DW, Mukhopadhyay T, Liu Y, Fujiwara T, Roth JA. Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer. Hum Gene Ther. 4:1993;617-624.
72. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science. 265:1994;1582-1584.
73. Van Meir EG, Polverini PJ, Chazin VR, Su Huang HJ, De Tribolet N, Cavenee WK. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat Genet. 8:1994;171-176.
74. Caplen NJ, Alton EW, Middleton PG, Dorin JR, Stevenson BJ, Gao X, Durham SR, Jeffery PK, Hodson ME, Coutelle C. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med. 1:1995;39-46.
75. Yu D, Matin A, Xia W, Sorgi F, Huang L, Hung MC. Liposome-mediated in vivo E1A gene transfer supressed dissemination of ovarian cancer cells that overexpress HER-2/neu. Oncogene. 11:1995;1383-1388.
76. Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA, Roth JA. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst. 86:1994;1458-1462.
77. Roth JA. Modification of tumor suppressor gene expression in non-small cell lung cancer (NSCLC) with a retroviral vector expressing wildtype (normal) p53. Hum Gene Ther. 7:1996;861-874.
78. Wills KN, Maneval DC, Menzel P, Harris MP, Sutjipto S, Vaillancourt MT, Huang WM, Johnson DE, Anderson SC, Wen SF. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther. 5:1994;1079-1088.
79. Zhang WW, Alemany R, Wang J, Koch PE, Ordonez NG, Roth JA. Safety evaluation of Ad5CMV-p53 in vitro and in vivo. Hum Gene Ther. 6:1995;155-164.
80. Mujoo K, Maneval DC, Anderson SC, Gutterman JU. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene. 12:1996;1617-1623.
81. Clayman GL, El-Naggar AK, Roth JA, Zhang WW, Goepfert H, Taylor DL, Liu TJ. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res. 55:1995;1-6.
82. Eastham JA, Hall SJ, Sehgal I, Wang J, Timme TL, Yang G, Connell-Crowley L, Elledge SJ, Zhang WW, Harper JW. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res. 55:1995;5151-5155.
83. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. 54:1994;2287-2291.
84. Roth JA. Modification of tumor suppressor gene expression and induction of apoptosis in non-small cell lung cancer (NSCLC) with an adenovirus vector expressing wildtype p53 and cisplatin. Hum Gene Ther. 7:1996;1013-1030.
85. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 265:1994;346-355.
86. Zhang W, Guo XY, Hu GY, Liu WB, Shay JW, Deisseroth AB. A temperature-sensitive mutant of human p53. EMBO J. 13:1994;2535-2544.
87. Da Costa LT, Jen J, He T-C, Chan TA, Kinzler K, Vogelstein B. Converting cancer genes into killer genes. of special interest Proc Natl Acad Sci USA. 93:1996;4192-4196 An ingenious gene therapy strategy utilizing endogenous cancer-specific genes. Although significant improvements need to be addressed in this approach for technical feasibility, the authors have successfully addressed two major issues in the gene therapy approach to treatment of cancer: specificity of targeting to cancer cells and generation of a cytotoxic bystander effect.
88. + cytotoxic T-cells. Cancer Res. 53:1993;3257-3261.
89. Carbone DP, Minna JD. In vivo gene therapy of human lung cancer using wild-type p53 delivered by retrovirus. J Natl Cancer Inst. 86:1994;1437-1438.
90. Hollstein M, Shimer B, Greenblatt M, Soussi T, Hovig E, Montesano R, Harris CC. Somatic point mutations in the p53 gene of human tumors and cell line: updated compilation. Nucleic Acids Res. 24:1996;141-146.